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OBJECTIVE: This study aimed to assess the circulating levels of activated nuclear factor kappa B p65 and
monocyte chemotactic protein-1 in diabetic retinopathy patients who were taking antihyperglycemic and
antihypertensive drugs.
METHODS: In total, 235 healthy controls and 371 Type 2 diabetic patients [171 without retinopathy (DNR) and
200 patients with retinopathy (diabetic retinopathy)] were recruited for this study. Plasma and the nuclear
fraction of peripheral blood mononuclear cells were isolated for the quantification of the monocyte
chemotactic protein-1 and nuclear factor kappa B p65 levels, respectively.
RESULTS: Non-medicated diabetic retinopathy patients had significantly higher levels of activated nuclear
factor kappa B p65 and plasma monocyte chemotactic protein-1 than DNR patients. Diabetic retinopathy
patients who were taking antihyperglycemic and antihypertensive drugs showed significant reductions in both
the nuclear factor kappa B p65 and monocyte chemotactic protein-1 levels compared with the non-medicated
patients.
CONCLUSION: This study demonstrated the significant attenuation of both the nuclear factor kappa B p65 and
circulating monocyte chemotactic protein-1 levels in diabetic retinopathy patients taking antihyperglycemic
and antihypertensive drugs.
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& INTRODUCTION
The increasing prevalence of diabetes mellitus (DM)
worldwide will inevitably be accompanied by an increased
development of irreversible DM complications, including
diabetic retinopathy (DR). DR is the most common
complication among patients with type 2 DM (1), and it is
the leading cause of preventable vision impairment among
working-age adults (2). More than 50% of type 2 DM
patients are likely to experience DR within 20 years after
diagnosis (3). DR is characterized by microvascular lesions
such as microaneurysms, basement membrane thickening,
loss of pericytes leading to blood barrier dysfunction and
pre-retinal neovascularization (4).
The presence of oxidative stress and the generation of
reactive oxygen species and advanced glycation end
products are known to contribute to the development of
DR (4). The role of inflammation in the development of DR
is supported by increasing evidence that has shown the
involvement of various cytokines and inflammatory cells in
the pathogenesis of DR (5). Prolonged hyperglycemia in a
person with type 2 DM creates a hypoxic state that triggers
abnormal local leukocyte-endothelial interactions, which
lead to retinal microvascular damage (6). Nuclear factor
kappa B (NF-kB) is a ‘‘redox-sensitive’’ nuclear transcription
factor present in many cell types that mainly regulates
immune and inflammatory responses as well as apoptosis
by controlling the expression of numerous genes coding for
pro-inflammatory cytokines, chemokines, inflammatory
enzymes and adhesion molecules (7) that are essential for
leukocyte migration and adherence to vascular endothelial
cells. Increased NF-kB expression had been demonstrated in
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many inflammatory diseases (7). Monocyte chemotactic
protein-1 (MCP-1) is a chemokine regulated by NF-kB that is
mainly expressed in smooth muscle cells, macrophages,
endothelial cells and adipocytes (8). Its main function is to
recruit circulating monocytes into the subendothelial cell
layer of the blood vessel wall, and it has been reported to be
involved in the pathogenesis of atherosclerosis, cardiovas-
cular disease, obesity and insulin resistance (8).
The 1998 United Kingdom Prospective Diabetes Study
provided the first evidence that early intervention with oral
glucose-lowering and antihypertensive drugs reduced the
incidence of diabetic complications and improved the
survival of type 2 DM patients (9-10). However, it is
uncertain whether this beneficial effect was derived directly
from tight glycemic and blood pressure control or through
other means of action. The recent large-scale Diabetic
Retinopathy Candesartan control trial reported that anti-
hypertensive drugs (angiotensin-converting enzyme inhibi-
tors and angiotensin II receptor antagonists) delayed the
progression of DR (11-12). Antihyperglycemic and anti-
hypertensive drugs are believed to possess anti-inflamma-
tory and endothelial-dysfunction modulating effects
independent of their blood glucose- and blood pressure-
lowering properties. Thus, this study aimed to assess the
circulating levels of activated peripheral blood mononuclear
cell (PBMC) NF-kB p65 and plasma MCP-1 in DR patients
treated with antihyperglycemic and antihypertensive drugs.
& METHODS
Study population
The study subjects were recruited from the diabetes and
ophthalmology clinics at the University Malaya Medical
Center, Malaysia, between September 2009 and October
2011. DM had been previously diagnosed according to the
World Health Organization criteria. A total of 371 unrelated
Type 2 DM patients [171 patients without retinopathy
(DNR) and 200 patients with retinopathy (DR)] (210 men,
161 women) aged 58.2¡9.7 years (mean¡SD; range, 35 to
78 years) were recruited for this study. Detailed medical
histories and socio-demographic data for each patient were
noted. The patients were carefully selected by excluding any
patients with a previous history of inflammatory disease
who had received anti-inflammatory drug treatment or
antioxidant supplements. Type 1 DM patients and type 2
DM patients with complications other than retinopathy
were also excluded from the study. The non-retinopathy
controls were recruited from among blood-donor volun-
teers. They consisted of 235 unrelated healthy subjects (134
men, 101 women) aged 57.1¡4.1 years (mean¡SD; range,
45 to 65 years). Both the DNR patients and healthy subjects
were confirmed to be free from any diabetic complications
including retinopathy by attending doctors and ophthal-
mologists. Written informed consent was obtained from
each subject prior to sample collection.
All of the DR patients underwent a complete eye
examination that included dilated retinal examination and
seven-field stereoscopic Diabetic Retinopathy Study retinal
photography (13). The color fundus photographs were
graded for DR severity in a blinded fashion by two
independent ophthalmologists at the University of Malaya
Eye Research Center, Malaysia. The modified Early
Treatment of Diabetic Retinopathy Study Airlie House
classification of DR was used to grade the retinopathy into
non-proliferative diabetic retinopathy (NPDR) and prolif-
erative diabetic retinopathy (PDR) (14). Among the DR
patients, 26 had mild NPDR, 85 had moderate NPDR, 14
had severe NPDR and 75 had PDR. The study was
performed in adherence to the principles of the 1983
Declaration of Helsinki and approved by the Medical
Ethics Review Committee of the University Malaya
Medical Center, Malaysia (IRB reference number: 744.12).
Sample collection and preparation
Six milliliters of blood was drawn from patients and
control subjects. Three ml of the freshly collected blood was
sent for routine blood examination at the Clinical Diagnostic
Laboratory of the University Malaya Medical Center. The
collected whole blood samples in EDTA tubes were
centrifuged for 15 minutes at 1000 xg. The plasma was
extracted and stored at -80 C˚ for the MCP-1 enzyme-linked
immunosorbent assay. Subsequently, the cell sediments of
the EDTA blood tubes were reconstituted with isotonic
phosphate-buffered saline solution. The peripheral blood
mononuclear cells (PBMCs) were then isolated as pre-
viously described (15) using a density gradient centrifuga-
tion method. PBMCs (approximately 4 million cells) were
subjected to nuclear extraction, and the extracted nuclear
fraction was used for the NF-kB p65 transcription factor
assay. Analysis of all of the samples was performed within 1
month after collection.
PBMC nuclear extraction
The nuclear fraction of the isolated PBMCs was extracted
using a commercially available nuclear extraction kit
(Cayman Chemical Company, MI, United States) according
to the manufacturer’s protocol. In brief, the extracted
PBMCs were collected in ice-cold PBS in the presence of
phosphatase inhibitors to prevent the events controlled by
dephosphorylation. The pelleted cells were then resus-
pended in ice-cold hypotonic buffer, causing cell swelling
and increased membrane fragility. The addition of detergent
(10% Nonidet P-40) ruptured the cell membranes and
released the cytoplasmic fraction while maintaining the
integrity of the nuclear membranes. After separation of the
cytoplasmic fraction from the nuclei by a brief centrifuga-
tion, the pelleted nuclei were lysed in ice-cold extraction
buffer containing a mixture of protease and phosphatase
inhibitors. The nuclear extract was then isolated by
microcentrifugation (14,000 xg for 10 minutes at 4 C˚) and
stored at -80 C˚.
Measurement of the NF-kB p65 levels in PBMCs
The levels of activated NF-kB p65 in the nuclei of PBMCs
were measured using a transcription factor assay kit
(Cayman Chemical Company, MI, United States). The kit
utilized a specific double-stranded DNA sequence contain-
ing an NF-kB response element to specifically bind the
activated NF-kB p65 in the nuclear extract. NF-kB p65 was
detected by the addition of a specific primary antibody
directed against NF-kB p65. A secondary antibody con-
jugated to horseradish peroxidase was added to provide a
sensitive colorimetric readout at 450 nm. The inter-assay
coefficient of variation was 8%. The nuclear protein
concentration was determined using a Bradford assay (16),
and the activated NF-kB p65 level was expressed as
arbitrary units per milligram of protein (AU/mg of nuclear
protein).
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Measurement of the plasma MCP-1 levels
The plasma MCP-1 levels were quantitatively measured
with a sandwich enzyme-linked immunosorbent assay
standard kit (RaybiotechH Inc., GA, United States) according
to the manufacturer’s protocol. The plate was coated with a
specific monoclonal antibody directed against human MCP-
1, and a polyclonal antibody conjugated to horseradish
peroxidase was used for sensitive colorimetric detection at
450 nm. The inter-assay coefficient of variation was 7.7%.
The mean minimal detectable level of MCP-1 was typically
less than 2 pg/ml. The results were expressed as pg/ml.
Statistical analysis
The continuous variables were checked for normality prior
to statistical analysis. A chi-squared test with one degree of
freedom (for dichotomous variables) and an unpaired t-test
(for continuous variables) were used to evaluate the
differences between the groups. Comparison of subgroups
was performed with one-way analysis of variance (ANOVA)
and Tukey’s post-hoc test. Associations between parameters
were determined by Pearson’s correlation coefficient (r) with
Bonferroni correction. A logistic regression model was used
to estimate the odds ratio (OR) and 95% confidence interval
(CI) for each risk factor for DR among the type 2 DM patients.
Statistical significance was set at p,0.05. All of the data were
analyzed using GraphPad PrismH for WindowsH version 5.02
(GraphPadH Software Inc., CA, United States).
& RESULTS
The general clinical parameters for the healthy controls
and the DNR and DR patients are listed in Table 1. Both the
DNR and DR patients showed significantly (p,0.05) higher
levels of glycated hemoglobin (HbA1c), total cholesterol,
high-density lipoprotein (HDL-C) and low-density lipopro-
tein (LDL-C), higher systolic blood pressures (SBP), a higher
prevalence of hypertension, a lower HLD/LDL ratio and
lower diastolic blood pressures (DBP) compared to the
healthy controls. When the two patient groups were
compared, the DR patients had significantly (p,0.05) higher
levels of HbA1c and total cholesterol, a longer duration of
DM and more subjects who received insulin treatment. No
significant differences (p.0.05) in gender, age, body mass
index (BMI), triglyceride levels, alanine aminotransferase
(ALT) levels or aspartate aminotransferase (AST) levels
were observed.
In this study, DR patients who were free from the
influence of antihyperglycemic and antihypertensive med-
ications had significantly higher levels of NF-kB p65 and
plasma MCP-1 than the healthy controls (Figure 1). In
addition, significantly higher levels of NF-kB p65 were
Table 1 - General clinical parameters of healthy controls and DNR and DR patients.
Demographics Ctrl (n = 235) DNR (n =171) DR (n=200)
Age (years) 57.1¡4.1 59.2¡9.6 57.2¡9.8
Gender (male/female) 134/101 100/71 110/90
Race (Malay/Chinese/Indian) 106/90/39 63/28/80a 70/47/83a
BMI (kg/m2) 25.6¡4.8 (n= 100) 27.2¡4.4 26.3¡5.0
HbA1c (%) 5.6¡0.4 (n= 100) 7.9¡1.8
a 8.9¡2.1a,b
SBP (mmHg) 124.0¡8.0 (n= 100) 136.5¡19.5a 139.3¡22.4a
DBP (mmHg) 83.0¡7.0 (n= 100) 79.0¡10.5a 78.4¡13.1a
Total cholesterol (mmol/l) 3.8¡0.6 (n= 100) 4.5¡1.0a 4.8¡1.5a,b
Triglycerides (mmol/l) 1.8¡1.3 (n= 100) 1.6¡0.7 1.7¡1.0
HDL-C (mmol/l) 1.0¡0.3 (n= 100) 1.2¡0.3a 1.2¡0.3a
LDL-C (mmol/l) 2.1¡0.5 (n= 100) 2.5¡0.9a 2.8¡1.2a
HDL-C/LDL-C ratio 0.6¡0.2 (n= 100) 0.5¡0.2a 0.5¡0.2a
ALT (IU/l) 30-65 c 37.8¡17.5 36.8¡24.6
AST (IU/l) 15-37 c 22.0¡14.0 22.8¡16.4
Diabetes duration (years) - 10.4¡7.9 15.7¡9.1b
Retinopathy duration (years) - - 5.0¡3.6
Current smoker (yes/no) 43/192 29/142 13/187a,b
Alcohol intake (yes/no) 70/165 24/147a 16/184a
Hypertension (yes/no) 0/235 104/67a 119/81a
Antihyperglycemic treatment
duration (years)
- 9.5¡5.5a (n = 107) 11.5¡7.5a (n = 130)
Antihyperglycemic medication
(yes/no)
0/235 107/64 a 130/70 a
Insulin (yes/no) 0/235 34/137 a 98/102 a,b
Oral medication (yes/no) 0/235 119/81 a 81/119 a,b
Antihypertensive treatment
duration (years)
- 7.0¡3.5 a (n = 104) 8.5¡4.0 a (n = 119)
Antihypertensive medication
(yes/no)
0/235 104/67 a 119/81 a
ACEI & ARA (yes/no) 0/235 67/104 a 83/117 a
CCB & Diuretics (yes/no) 0/235 37/134 a 36/164 a
The data are expressed as the mean¡ SD unless otherwise indicated; dichotomous variables are given in absolute numbers. ACEI, angiotensin-converting
enzyme inhibitors; ALT, alanine aminotransferase; ARA, angiotensin II receptor antagonists; AST, aspartate aminotransferase; BMI, body mass index; CCB,
calcium channel blockers; Ctrl, healthy controls; DBP, diastolic blood pressure; DNR, diabetic non-retinopathy; DR, diabetic retinopathy; HbA1c, glycated
hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and SBP, systolic blood pressure. ap,0.05 versus
healthy control; bp,0.05 versus DNR; cnormal value range provided.
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found in the DR and NPDR patients compared with the
DNR patients. Both the DNR and DR patients who were
taking antihyperglycemic and antihypertensive medications
showed lower levels of NF-kB p65 and plasma MCP-1
compared with the non-medicated patients (Table 2).
Further comparisons between the medicated and non-
medicated patients (NPDR and PDR) showed similar trends
in the results.
The correlation results observed in this study (Table 3)
were weak (r,0.5) but significant (p,0.05). The NF-kB p65
level was positively correlated with the plasma MCP-1 level
in healthy controls and DNR patients as well as with the
diabetes duration in both DNR and DR patients. In addition,
positive correlations were also observed between the NF-kB
p65 and HbA1c levels as well as the triglyceride level in the
DNR patients. Both the SBP and DM duration in the DNR
patients were positively correlated with the plasma MCP-1
level, but an inverse correlation was found between the
plasma MCP-1 and HDL-C levels. In DR patients, the
plasma MCP-1 level was positively correlated with the
HbA1c level, DM duration and retinopathy duration.
The risk factors for DR were investigated among the type
2 DM patients (DNR and DR) using a logistic regression
model (Table 4). High levels of HbA1c (OR = 1.20, p,0.05),
plasma MCP-1 (OR = 1.04, p,0.05) or activated NF-kB p65
(OR = 1.08, p,0.05) and long diabetes duration (OR = 1.08,
p,0.05) were risk factors for DR after adjusting for age,
gender and other metabolic factors. Antihyperglycemic
(OR = 0.81 for oral and OR = 0.63 for insulin, p,0.05 for
both) and antihypertensive (OR = 0.79, p,0.05) medications
were protective against the development of DR by type 2
DM patients.
& DISCUSSION
DR is a chronic, low-grade inflammatory disease caused
by the presence of microscopic signs of inflammation in the
retina such as vasodilatation, fluid exudation, leukocyte
Figure 1 - Comparison of the levels of (A) NF-kB p65 and (B) plasma MCP-1 in Ctrl (n = 235), DNR (n=50), DR (n=70), NPDR (n=40) and
PDR (n=30) patients who were not taking antihyperglycemic and antihypertensive medications. The data are expressed as the
mean¡SD. Ctrl, healthy controls; DNR, diabetic non-retinopathy; DR, diabetic retinopathy; NPDR, non-proliferative DR; PDR,
proliferative DR. ap,0.05 versus Ctrl; bp,0.05 versus DNR.
Table 2 - Comparison of the NF-kB p65 and plasma MCP-1 levels in DNR and DR patients with different clinical factors.
Parameters/groups Antihyperglycemic medication Antihypertensive medication
yes no yes no
NF-kB p65 (AU/mg)
DNR 5.0¡1.6a (107) 6.1¡3.2 (50) 4.9¡1.3a (104) 6.1¡3.2 (50)
DR 6.1¡2.8b (130) 8.1¡5.8 (70) 6.2¡3.3b (119) 8.1¡5.8 (70)
NPDR 6.0¡2.9c (85) 10.4¡8.1 (40) 5.2¡1.6c (74) 10.4¡8.1 (40)
PDR 5.6¡1.9d (45) 7.1¡4.5 (30) 5.2¡1.4d (45) 7.1¡4.5 (30)
MCP-1 (pg/ml)
DNR 13.4¡11.1a (107) 24.7¡19.8 (50) 12.1¡9.0a (104) 24.7¡19.8 (50)
DR 18.7¡14.4b (130) 30.5¡18.8 (70) 16.8¡12.1b (119) 30.5¡18.8 (70)
NPDR 20.8¡18.5c (85) 28.3¡19.8 (40) 20.4¡15.6c (74) 28.3¡19.8 (40)
PDR 15.6¡10.4d (45) 27.1¡17.3 (30) 18.6¡13.1d (45) 27.1¡17.3 (30)
The data are expressed as the mean¡SD; the number in the parentheses indicates the number of subjects. DNR, diabetic non-retinopathy; DR, diabetic
retinopathy; MCP-1, monocyte chemoattractant-1; NF-kB p65, nuclear factor kappa B p65; NPDR, non-proliferative diabetic retinopathy; and PDR,
proliferative diabetic retinopathy. ap,0.05 versus DNR with no antihyperglycemic and antihypertensive medication; bp,0.05 versus DR with no
antihyperglycemic and antihypertensive medication; cp,0.05 versus NPDR with no antihyperglycemic and antihypertensive medication; dp,0.05 versus
PDR with no antihyperglycemic and antihypertensive medication.
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migration and altered retinal blood flow (5). Previous
reports have shown that the local expression of MCP-1
and NF-kB in the retina as well as their levels in the vitreous
fluids are increased in PDR patients (17-18). This study
aimed to assess the circulating levels of activated NF-kB p65
in PBMCs and plasma MCP-1 in type 2 DM patients with
retinopathy who were taking antihyperglycemic and anti-
hypertensive drugs. The basal levels of plasma MCP-1 and
NF-kB p65 in the PBMCs of healthy controls in this study
were comparable to previously observed values (19-20). NF-
kB and MCP-1 could be involved in the pathogenesis of DR
due to the findings of significantly elevated levels of these
markers in non-medicated DR patients, and the plasma
MCP-1 level was positively correlated with retinopathy
duration.
In addition, both DM duration and HbA1c were found to
be positively correlated with both of the inflammatory
markers in DR patients. This confirms that prolonged
hyperglycemia triggers inflammation, possibly by causing
abnormal local leukocyte-endothelial interaction in DR
patients. Inflammatory chemokines are also potential
angiogenic factors (21). Therefore, MCP-1 may act with
vascular endothelial growth factor (5) to promote angiogen-
esis in the retina and cause neovascularization in PDR. The
positive correlation between the NF-kB p65 and plasma
MCP-1 levels in the healthy controls and DNR patients
further supports the regulatory role of NF-kB on MCP-1.
Inflammatory chemokines, including MCP-1, also activate
NF-kB, leading to the generation of reactive oxygen species
and creating a vicious cycle (7). This study also showed that
Table 3 - Pearson correlations between NF-kB, MCP-1 and
several clinical parameters of different clinical groups.
Biochemical parameters Pearson r p-value
Ctrl
NF-kB p65/MCP-1 0.19 ,0.01
DNR
NF-kB p65/MCP-1 0.18 ,0.05
NF-kB p65/HbA1c 0.18 ,0.05
NF-kB p65/diabetes duration 0.20 ,0.05
NF-kB p65/triglycerides 0.19 ,0.05
MCP-1/HDL-C - 0.17 ,0.05
MCP-1/diabetes duration 0.16 ,0.05
MCP-1/SBP 0.17 ,0.05
DR
NF-kB p65/diabetes duration 0.17 ,0.05
MCP-1/HbA1c 0.25 ,0.01
MCP-1/diabetes duration 0.26 ,0.001
MCP-1/retinopathy duration 0.16 ,0.05
Ctrl, healthy controls; DNR, diabetic non-retinopathy; DR, diabetic
retinopathy; HbA1c, glycated hemoglobin; HDL-C, high-density
lipoprotein cholesterol; MCP-1, monocyte chemoattractant protein-1; NF-
kB p65, nuclear factor kappa B p65; and SBP, systolic blood pressure.
Table 4 - Risk assessment for DR in type 2 DM patients.
Characteristics Unadjusted model Adjusted model
a
OR (95% CI) p-value OR (95% CI) p-value
Age (years) 0.96 (0.93-1.00) 0.052
Gender Female 1.00 (reference)
Male 0.87 (0.58-1.31) 0.511
BMI (kg/m2) 0.96 (0.92-1.01) 0.099
SBP (mmHg) 1.01 (1.00-1.02) 0.274
DBP (mmHg) 1.00 (0.98-1.02) 0.736
Diabetes duration (years) 1.08 (1.05-1.11) 0.000 1.08 (1.04-1.13) 0.000
HbA1c (%) 1.34 (1.18-1.53) 0.000 1.20 (1.00-1.44) 0.046
Total cholesterol (mmol/l) 1.25 (1.04-1.49) 0.018 1.46 (0.76-2.79) 0.251
Triglycerides (mmol/l) 1.25 (0.96-1.63) 0.100
HDL-C (mmol/l) 1.02 (0.53-1.95) 0.952
LDL-C (mmol/l) 1.25 (1.01-1.54) 0.045 0.68 (0.33-1.42) 0.308
ALT (IU/l) 1.00 (0.99-1.01) 0.998
AST (IU/l) 1.00 (0.99-1.02) 0.615
Current Smokers No 1.00 (reference)
Yes 0.51 (0.30-0.87) 0.013 0.40 (0.15-1.03) 0.057
Alcohol intake No 1.00 (reference)
Yes 0.58 (0.31-1.07) 0.081
Hypertension No 1.00 (reference)
Yes 0.79 (0.49-1.28) 0.347
Insulin antihyperglycemic medication
No 1.00 (reference)
Yes 0.74 (0.37-5.92) 0.000 0.63 (0.16-4.66) 0.018
Oral antihyperglycemic medication
No 1.00 (reference)
Yes 0.67 (0.40-1.12) 0.003 0.81 (0.50-1.78) 0.033
Antihypertensive medication
No 1.00 (reference)
Yes 0.56 (0.37-0.86) 0.008 0.79 (0.40-1.58) 0.040
NF-kB p65 (AU/mg) 1.11 (1.01-1.18) 0.005 1.08 (0.98-1.19) 0.030
MCP-1 (pg/ml) 1.05 (1.03-1.06) 0.000 1.04 (1.02-1.07) 0.002
Type 2 DM patients (DNR and DR) (n= 371) were included in the analysis model. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI,
body mass index; CI, confidence interval; DBP, diastolic blood pressure; DR, diabetic retinopathy; HbA1c, glycated hemoglobin; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MCP-1, monocyte chemoattractant protein-1; NF-kB p65, nuclear factor kappa B p65;
OR, odds ratio; and SBP, systolic blood pressure. a Adjusted for age, gender and metabolic risk factors (BMI, HbA1c and DM duration).
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NF-kB p65 was positively correlated with the triglyceride
levels and that the plasma MCP-1 levels were inversely
associated with the HDL-C levels in DNR patients. The
above observations are in agreement with a previous report
suggesting the possible involvement of MCP-1 in obesity-
related health complications (8).
The 1998 United Kingdom Prospective Diabetes Study,
involving 3,867 type 2 DM patients, demonstrated that early
intervention with oral glucose-lowering and antihyperten-
sive drugs reduced the incidence of diabetic complications
and improved the survival of these patients (9-10).
However, there was no evidence to show whether this
beneficial effect was derived directly from tight glycemic
and blood pressure control or through other means of
action. In this study, approximately 60% of the DM patients
received antihyperglycemic and antihypertensive medica-
tions. The patient groups (DNR, DR, NPDR and PDR) who
were taking either antihyperglycemic (insulin, biguanides,
sulfonylureas and thiazolidinediones) or antihypertensive
drugs (angiotensin-converting enzyme inhibitors, calcium
channel blockers and angiotensin II receptor antagonists)
had significantly lower levels of NF-kB p65 and plasma
MCP-1 compared with the non-medicated group. These
findings may explain the beneficial effects of the antihy-
perglycemic and antihypertensive drugs on diabetic micro-
vascular complications that were observed in the United
Kingdom Prospective Diabetes Study. However, this study
did not investigate the local effect of these medications on
the expression of NF-kB and MCP-1 in the retina of DR
patients. A previous report showed that a reduction of local
retinal inflammation and the NF-kB and MCP-1 expression
levels was found in cultured murine endothelial cells
treated with antihypertensive drugs (22). Thus, we spec-
ulate that the vitreous levels of NF-kB and MCP-1 in the DR
patients are concurrently reduced with the circulating levels
of these pro-inflammatory markers.
This transversal study could not identify the actual
mechanism by which antihypertensive drugs ameliorate
DR. A local renin–angiotensin system exists in retinal glial
cells (23), and it is upregulated in DR (24). Angiotensin II is
a well-known vasoconstrictor, and it may induce vascular
endothelial growth factors that lead to retinal neovascular-
ization (24), a common microscopic sign in PDR. We
speculate that the beneficial effect of antihypertensive
treatments on DR could partly be due to blocking of the
renin–angiotensin system. In addition, a cross-interaction
between the advanced glycation end product (AGE)-
receptor for AGE (RAGE) and the renin-angiotensin system
has been proposed in the pathogenesis of DR (25).
Previously, we have shown that RAGE is a pertinent factor
leading to DR, and its genetic variants are associated with
the development of DR (26). Antihypertensive drugs may
reduce the AGE-RAGE interaction by attenuating the NF-kB
that controls the cellular expression of RAGE. It should be
noted that NF-kB is not the only regulator of diabetes-
induced inflammation in DR. The presence of hypoxia in DR
could activate another transcription factor, hypoxia induci-
ble factor 1 (27), which was not investigated in this study.
In conclusion, this study showed significant attenuation
of both the PBMC NF-kB p65 and circulating MCP-1 levels
in DR patients who were taking antihyperglycemic and
antihypertensive drugs. Nevertheless, a prospective case-
control study is required to substantiate our findings.
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